| Related Information: |
| The United Kingdom: Ulipristal acetate 5mg (Esmya): further restrictions due to ... 上载于 2021-02-19 |
| European Union: Ulipristal acetate for uterine fibroids: EMA recommends restrict... 上载于 2020-11-14 |
| Singapore: Voluntary withdrawal of Esmya (ulipristal acetate) Tablet 5mg by Zuel... 上载于 2020-10-10 |
| Canada: FIBRISTAL (ulipristal acetate tablets, 5 mg): Voluntary withdrawal in Ca... 上载于 2020-10-05 |
| Canada: Recall: Fibristal 5mg Tablet (English only) 上载于 2020-09-29 |
| Singapore: Temporary suspension of sales of Esmya (ulipristal acetate) tablet 5 ... 上载于 2020-09-19 |
| Canada: Health Canada reviews safety of drug Fibristal (ulipristal acetate) agai... 上载于 2020-09-17 |
| European Union: PRAC recommends revoking marketing authorisation of ulipristal a... 上载于 2020-09-05 |
| 台湾：回收恩惜膜5毫克锭剂Esmya 5mg tablets 上载于 2020-04-14 |
| Singapore: Temporary suspension of the sales of Esmya (ulipristal acetate) Table... 上载于 2020-04-03 |
| Singapore: Temporary suspension of the sales of Esmya (ulipristal acetate) Table... 上载于 2020-03-27 |
| The United Kingdom: Class 2 Medicines Recall: Esmya 5mg tablets (English only) 上载于 2020-03-19 |
| The United Kingdom: Esmya (ulipristal acetate): suspension of the licence due to... 上载于 2020-03-19 |
| European Union: Suspension of ulipristal acetate for uterine fibroids during ong... 上载于 2020-03-14 |
| Singapore: Risk of serious liver injury with Esmya (ulipristal acetate) (English... 上载于 2019-09-13 |
| Singapore: Esmya (ulipristal acetate) and risk of serious liver injury (English ... 上载于 2019-04-04 |
| Canada: Health Canada safety review finds possible link between Fibristal and ri... 上载于 2019-01-12 |
| Canada: Summary Safety Review - Fibristal (5 mg ulipristal acetate) - Assessing ... 上载于 2018-09-11 |
| 英国：Esmya (醋酸乌利司他)和严重肝脏损害的风险：新的使用限制及在治疗前、治疗期间和治疗后肝功能监测的要求 上载于 2018-08-25 |
| 新加坡：Esmya (醋酸乌利司他)肝脏损害风险的重要安全更新 上载于 2018-06-12 |
| 欧洲联盟：Esmya：减少罕见但严重肝脏损伤风险的新措施 – 欧洲药物监管局总结治疗子宫纤维瘤药物的审查 上载于 2018-06-02 |
| 欧洲联盟：药物警戒风险评估委员会建议减少治疗纤维瘤药物Esmya罕见但严重肝脏损伤风险的新措施 – 治疗期间应定期接受肝脏测试 上载于 2018-05-19 |
| 欧洲联盟：在欧洲药物监管局进行审查时，服用Esmya (乌利司他)治疗子宫纤维瘤的女性应定期接受肝脏测试。同时新患者不应开始接受治疗。 上载于 2018-04-14 |
| 加拿大：卫生局审查Fibristal (醋酸乌利司他)新的潜在安全风险，一种用于治疗纤维瘤的药物 上载于 2018-03-16 |
| 英国：治疗子宫纤维瘤的Esmya (醋酸乌利司他)：不应开始或重新开始治疗;为现正使用和近来有使用药物的病人监测肝功能 上载于 2018-03-09 |
| 新加坡：Esmya (醋酸乌利司他) Tablet 5mg潜在肝脏损害风险的重要安全更新 上载于 2018-02-21 |
| 英国：Esmya：不应开始新的疗程直到另行通知 上载于 2018-02-20 |
| Women taking Esmya for uterine fibroids to have regular liver tests while EMA re... 上载于 2018-02-12 |
| 欧洲联盟：在欧洲药物监管局进行审查时，服用Esmya治疗子宫纤维瘤的女性应定期接受肝脏测试。同时新患者不应开始接受治疗。 上载于 2018-02-10 |
| 欧洲联盟：欧洲药物监管局开始审查子宫纤维瘤药物Esmya - 肝脏损害个案引起的审查 上载于 2017-12-02 |
